{
  "generated_rows": [
    {
      "company": "Pfizer",
      "total_score": 8.1,
      "fit_score": 2.0,
      "urgency_score": 3.0,
      "access_score": 2.0,
      "trigger_summary": "trial_candidate: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | trial_candidate: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | trial_candidate: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06215118",
        "https://clinicaltrials.gov/study/NCT06152575",
        "https://clinicaltrials.gov/study/NCT05020236",
        "https://clinicaltrials.gov/study/NCT06057402",
        "https://clinicaltrials.gov/study/NCT05090566",
        "https://clinicaltrials.gov/study/NCT04649359"
      ]
    },
    {
      "company": "Cullinan Therapeutics Inc.",
      "total_score": 7.8,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis | trial_candidate: A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07041099",
        "https://clinicaltrials.gov/study/NCT06994143",
        "https://clinicaltrials.gov/study/NCT05879744"
      ]
    },
    {
      "company": "TScan Therapeutics, Inc.",
      "total_score": 7.8,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | trial_candidate: A Long Term Follow-up Study of TScan TCR-T Products | trial_candidate: A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05973487",
        "https://clinicaltrials.gov/study/NCT06976736",
        "https://clinicaltrials.gov/study/NCT05473910"
      ]
    },
    {
      "company": "Hebei Senlang Biotechnology Inc., Ltd.",
      "total_score": 7.65,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | trial_candidate: Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07244380",
        "https://clinicaltrials.gov/study/NCT07244406"
      ]
    },
    {
      "company": "Corregene Biotechnology Co., Ltd",
      "total_score": 7.65,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | trial_candidate: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06767046",
        "https://clinicaltrials.gov/study/NCT06358053"
      ]
    },
    {
      "company": "Carina Biotech Limited",
      "total_score": 7.5,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05759728"
      ]
    },
    {
      "company": "Shanghai Ruiliyuan Biotechnology Co., Ltd.",
      "total_score": 7.5,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06515314"
      ]
    },
    {
      "company": "SCG Cell Therapy Pte. Ltd.",
      "total_score": 7.3,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | trial_candidate: A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | trial_candidate: Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05417932",
        "https://clinicaltrials.gov/study/NCT06617000",
        "https://clinicaltrials.gov/study/NCT06505551"
      ]
    },
    {
      "company": "Guangzhou FineImmune Biotechnology Co., LTD.",
      "total_score": 7.15,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors | trial_candidate: Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06942143",
        "https://clinicaltrials.gov/study/NCT03891706"
      ]
    },
    {
      "company": "AstraZeneca",
      "total_score": 7.1,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 2.0,
      "trigger_summary": "trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | trial_candidate: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | trial_candidate: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06542250",
        "https://clinicaltrials.gov/study/NCT06564038",
        "https://clinicaltrials.gov/study/NCT05877599",
        "https://clinicaltrials.gov/study/NCT06218914",
        "https://clinicaltrials.gov/study/NCT06005493",
        "https://clinicaltrials.gov/study/NCT07215585",
        "https://clinicaltrials.gov/study/NCT07201558"
      ]
    },
    {
      "company": "Beijing Yongtai Ruike Biotechnology Company Ltd",
      "total_score": 7.0,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06179524"
      ]
    },
    {
      "company": "Nkarta, Inc.",
      "total_score": 7.0,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05020678"
      ]
    },
    {
      "company": "TCRCure Biopharma Ltd.",
      "total_score": 7.0,
      "fit_score": 3.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05881525"
      ]
    },
    {
      "company": "Bioray Laboratories",
      "total_score": 6.65,
      "fit_score": 3.0,
      "urgency_score": 2.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Universal CAR-T Cell Therapy for NHL | trial_candidate: Universal CAR-T Cell Therapy for Refractory Lupus Nephritis",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07248163",
        "https://clinicaltrials.gov/study/NCT06681337"
      ]
    },
    {
      "company": "Galapagos NV",
      "total_score": 6.5,
      "fit_score": 3.0,
      "urgency_score": 2.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06652633"
      ]
    },
    {
      "company": "Regeneron Pharmaceuticals",
      "total_score": 6.1,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | trial_candidate: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma | trial_candidate: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05828511",
        "https://clinicaltrials.gov/study/NCT06097364",
        "https://clinicaltrials.gov/study/NCT06149286",
        "https://clinicaltrials.gov/study/NCT06091865",
        "https://clinicaltrials.gov/study/NCT06469281",
        "https://clinicaltrials.gov/study/NCT05730036",
        "https://clinicaltrials.gov/study/NCT06787612",
        "https://clinicaltrials.gov/study/NCT07222761"
      ]
    },
    {
      "company": "Guangzhou Bio-gene Technology Co., Ltd",
      "total_score": 6.0,
      "fit_score": 3.0,
      "urgency_score": 2.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07196124"
      ]
    },
    {
      "company": "Carbiogene Therapeutics Co. Ltd.",
      "total_score": 6.0,
      "fit_score": 3.0,
      "urgency_score": 2.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT04803929"
      ]
    },
    {
      "company": "Shanghai First Song Biotechnology Co., LTD",
      "total_score": 6.0,
      "fit_score": 3.0,
      "urgency_score": 2.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06532643"
      ]
    },
    {
      "company": "Excyte Biopharma Ltd",
      "total_score": 5.95,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 | trial_candidate: Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus | trial_candidate: A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06565689",
        "https://clinicaltrials.gov/study/NCT07010835",
        "https://clinicaltrials.gov/study/NCT06574568",
        "https://clinicaltrials.gov/study/NCT06982729"
      ]
    },
    {
      "company": "Janssen Research & Development, LLC",
      "total_score": 5.8,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | trial_candidate: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05201781",
        "https://clinicaltrials.gov/study/NCT03399799",
        "https://clinicaltrials.gov/study/NCT04634552"
      ]
    },
    {
      "company": "Genmab",
      "total_score": 5.8,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_candidate: GEN1047 for Solid Tumors - First in Human (FIH) Trial | trial_candidate: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05660967",
        "https://clinicaltrials.gov/study/NCT05180474",
        "https://clinicaltrials.gov/study/NCT04623541"
      ]
    },
    {
      "company": "Amgen",
      "total_score": 5.8,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | trial_candidate: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | trial_candidate: Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06555796",
        "https://clinicaltrials.gov/study/NCT04221542",
        "https://clinicaltrials.gov/study/NCT06613100"
      ]
    },
    {
      "company": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
      "total_score": 5.65,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06297226",
        "https://clinicaltrials.gov/study/NCT06121843"
      ]
    },
    {
      "company": "Miltenyi Biomedicine GmbH",
      "total_score": 5.65,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: MB-dNPM1-TCR.1 in Relapsed/Refractory AML | trial_candidate: MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06424340",
        "https://clinicaltrials.gov/study/NCT03853616"
      ]
    },
    {
      "company": "Takeda",
      "total_score": 5.65,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma | trial_candidate: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06980480",
        "https://clinicaltrials.gov/study/NCT05020015"
      ]
    },
    {
      "company": "Immunocore Ltd",
      "total_score": 5.65,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | trial_candidate: Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06840119",
        "https://clinicaltrials.gov/study/NCT03070392"
      ]
    },
    {
      "company": "Boehringer Ingelheim",
      "total_score": 5.65,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: DAREON\u2122-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | trial_candidate: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05882058",
        "https://clinicaltrials.gov/study/NCT05916313"
      ]
    },
    {
      "company": "Arsenal Biosciences, Inc.",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07285694"
      ]
    },
    {
      "company": "Cabaletta Bio",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06359041"
      ]
    },
    {
      "company": "Fate Therapeutics",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06308978"
      ]
    },
    {
      "company": "Novartis Pharmaceuticals",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT06675864"
      ]
    },
    {
      "company": "AbbVie",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | trial_collaborator: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT03933735",
        "https://clinicaltrials.gov/study/NCT05660967",
        "https://clinicaltrials.gov/study/NCT04623541"
      ]
    },
    {
      "company": "Eli Lilly and Company",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) | trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07101328",
        "https://clinicaltrials.gov/study/NCT04623541"
      ]
    },
    {
      "company": "Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT04471727"
      ]
    },
    {
      "company": "Keymed Biosciences Co.Ltd",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07175493"
      ]
    },
    {
      "company": "Ouro Medicines",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: OM336 in Seropositive Autoimmune Diseases",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07229144"
      ]
    },
    {
      "company": "Incyte Corporation",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT07195916"
      ]
    },
    {
      "company": "MacroGenics",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05362773"
      ]
    },
    {
      "company": "Lyell Immunopharma, Inc.",
      "total_score": 5.5,
      "fit_score": 1.0,
      "urgency_score": 3.0,
      "access_score": 1.0,
      "trigger_summary": "trial_candidate: Study of LYL314 in Aggressive Large B-Cell Lymphoma",
      "evidence_links": [
        "https://clinicaltrials.gov/study/NCT05826535"
      ]
    }
  ],
  "target_roles": [
    "Director/VP, Translational Medicine (Oncology/Immunology)",
    "Head/Director, Clinical Biomarkers / Translational Biomarkers",
    "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
    "Director, Bioassay / Potency / Analytical Development",
    "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
  ]
}